The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review
Abstract
Purpose: Tumor lysis syndrome (TLS) has recently been subclassified into either laboratory TLS or clinical TLS, and a grading system has been established. Standardized guidelines, however, are needed to aid in the stratification of patients according to risk and to establish prophylaxis and treatment recommendations for patients at risk or with established TLS. Methods: A panel of experts in pediatric and adult hematologic malignancies and TLS was assembled to develop recommendations and guidelines for TLS based on clinical evidence and standards of care. A review of relevant literature was also used. Results: New guidelines are presented regarding the prevention and management of patients at risk of developing TLS. The best management of TLS is prevention. Prevention strategies include hydration and prophylactic rasburicase in high-risk patients, hydration plus allopurinol or rasburicase for intermediate-risk patients, and close monitoring for low-risk patients. Primary management of established TLS involves similar recommendations, with the addition of aggressive hydration and diuresis, plus allopurinol or rasburicase for hyperuricemia. Alkalinization is not recommended. Although guidelines for rasburicase use in adults are provided, this agent is currently only approved for use in pediatric patients in the United States. Conclusion: The potential severity of complications resulting from TLS requires measures for prevention in high-risk patients and prompts treatment in the event that symptoms arise. Recognition of risk factors, monitoring of at-risk patients, and appropriate interventions are the key to preventing or managing TLS. These guidelines should assist in the prevention of TLS and improve the management of patients with established TLS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumour lysis syndrome: new therapeutic strategies and classification
Cairo, M. S., & Bishop, M. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05094.x · Cited by 1,076
Self-citationGoldman, S. C., Holcenberg, J. S., Finklestein, J. Z., Hutchinson, R., Kreissman, S., Johnson, F. L., Tou, C., Harvey, E., Morris, E., & Cairo, M. S. (2001) · Blood · doi:10.1182/blood.v97.10.2998 · Cited by 477
Self-citationCohen, L. F., Balow, J. E., MAGRATH, I. T., Poplack, D. G., & Ziegler, J. L. (1980) · The American Journal of Medicine · doi:10.1016/0002-9343(80)90286-7 · Cited by 431
Pui, C.-H., Mahmoud, H. H., Wiley, J. M., Woods, G. M., Leverger, G., Camitta, B., Hastings, C., Blaney, S. M., Relling, M. V., & Reaman, G. H. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.697 · Cited by 361
Self-citationAbadie, V., Badell, E., Douillard, P., Ensergueix, D., Leenen, P. J. M., Tanguy, M., Fiette, L., Saeland, S., Gicquel, B., & Winter, N. (2005) · Blood · doi:10.1182/blood-2005-03-1281 · Cited by 355
Coiffier, B., Mounier, N., Bologna, S., Fermé, C., Tilly, H., Sonet, A., Christian, B., Casasnovas, O., Jourdan, E., Belhadj, K., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.115 · Cited by 237
Self-citationAcute tumor lysis syndrome in solid tumors—a case report and review of the literature
Baeksgaard, L., & Sørensen, J. B. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0556-x · Cited by 202
Jeha, S., Kantarjian, H., Irwin, D., Shen, V, Shenoy, S., Blaney, S., Camitta, B., & Pui, C.-H. (2005) · Leukemia · doi:10.1038/sj.leu.2403566 · Cited by 181
Self-citationUrate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies
Pui, C.-H., Relling, M., Lascombes, F., Harrison, P., Struxiano, A., Mondesir, J.-M., Ribeiro, R., Sandlund, J., Rivera, G., Evans, W., et al. (1997) · Leukemia · doi:10.1038/sj.leu.2400850 · Cited by 174
Self-citationBiochemistry of Uric Acid and Its Relation to Gout
Seegmiller, J. E., Laster, L., & Howell, R. R. (1963) · New England Journal of Medicine · doi:10.1056/nejm196303282681306 · Cited by 168
Jeha, S. (2001) · Seminars in Hematology · doi:10.1016/s0037-1963(01)90037-x · Cited by 161
Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy.
Conger, J. D., & Falk, S. A. (1977) · Journal of Clinical Investigation · doi:10.1172/jci108700 · Cited by 154
Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer
Bosly, A., Sonet, A., PINKERTON, C. R., et al. (2003) · Cancer · doi:10.1002/cncr.11612 · Cited by 153
Annemans, L., Moeremans, K., Lamotte, M., et al. (2002) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819021000054661 · Cited by 153
CD molecules 2005: human cell differentiation molecules
Zola, H., Swart, B., Nicholson, I., AASTED, B., Bensussan, A., Boumsell, L., Buckley, C., Clark, G. J., Drbal, K., Engel, P., et al. (2005) · Blood · doi:10.1182/blood-2005-03-1338 · Cited by 149
Pui, C., Jeha, S., Irwin, D. H., et al. (2001) · Leukemia · doi:10.1038/sj.leu.2402235 · Cited by 148
Self-citationKunkel, L., Wong, A., Maneatis, T., Nickas, J., Brown, T., Grillo-López, A. J., Benyunes, M., Grobman, B., & Dillman, R. O. (2000) · PubMed · Cited by 144
Krakoff, I. H., & MEYER, R. L. (1965) · JAMA · doi:10.1001/jama.1965.03090010007001 · Cited by 139
Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations
Yeldandi, A. V., Yeldandi, V. V., Kumar, S., Murthy, C. V. N., Wang, X., Alvares, K., Rao, M. S., & Reddy, J. K. (1991) · Gene · doi:10.1016/0378-1119(91)90622-i · Cited by 108
Allopurinol: Intravenous Use for Prevention and Treatment of Hyperuricemia
Smalley, R. V., Guaspari, A., Haase-Statz, S., Anderson, S. A., Cederberg, D., & Hohneker, J. A. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.8.1758 · Cited by 107
Conger, J. D. (1990) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30522-3 · Cited by 83
Stratification of treatment of stage 4 neuroblastoma patients based on N-myc amplification status
Kaneko, M., Nishihira, H., Mugishima, H., Ohnuma, N., Nakada, K., Kawa, K., Fukuzawa, M., Suita, S., Sera, Y., & Tsuchida, Y. (1998) · Medical and Pediatric Oncology · doi:10.1002/(sici)1096-911x(199807)31:1<27::aid-mpo6>3.0.co;2-1 · Cited by 58
Signal transduction inhibition: Results from phase I clinical trials in chronic myeloid leukemia
Druker, B. J. (2001) · Seminars in Hematology · doi:10.1016/s0037-1963(01)90112-x · Cited by 53
Urinary-Tract Stones Resulting from the Excretion of Oxypurinol
Landgrebe, A. R., Nyhan, W. L., & Coleman, M. (1975) · New England Journal of Medicine · doi:10.1056/nejm197503202921208 · Cited by 52
Modification of Uricaemia and the Excretion of Uric Acid Nitrogen by an Enzyme of Fungal Origin
Kissel, P., Lamarche, M., & Royer, R. Q. (1968) · Nature · doi:10.1038/217072a0 · Cited by 39
Adjuvant and neoadjuvant treatment of breast cancer
Gianni, L., Valagussa, P., Zambetti, M., Moliterni, A., Capri, G., & Bonadonna, G. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90042-9 · Cited by 36
Research works printed but not linked: 27
- Van den Berghe G: Purine and pyrimidine metabolism between millennia: What has been accomplished, what has to be done? Adv Exp Med Biol 486:1,2000-4, · doi:10.1007/0-306-46843-3_1
- 10.3816/CLM.2002.s.011 · doi:10.3816/clm.2002.s.011
- 10.1016/0002-9343(93)90174-N · doi:10.1016/0002-9343(93)90174-n
- 10.1016/0002-9343(75)90597-5 · doi:10.1016/0002-9343(75)90597-5
- 10.1002/1097-0142(19900715)66:2<246::AID-CNCR2820660209>3.0.CO;2-B · doi:10.1002/1097-0142(19900715)66:2<246::aid-cncr2820660209>3.0.co;2-b
- 10.1002/1097-0142(19851101)56:9<2295::AID-CNCR2820560926>3.0.CO;2-X · doi:10.1002/1097-0142(19851101)56:9<2295::aid-cncr2820560926>3.0.co;2-x
- 10.1001/archinte.1987.00370020193063 · doi:10.1001/archinte.1987.00370020193063
- 10.1200/JCO.1998.16.7.2313 · doi:10.1200/jco.1998.16.7.2313
- 10.1038/sj.leu.2402847 · doi:10.1038/sj.leu.2402847
- 10.1056/NEJM196603032740902 · doi:10.1056/nejm196603032740902
- 10.1007/BF00860751 · doi:10.1007/bf00860751
- 10.1016/S0022-3476(86)80387-0 · doi:10.1016/s0022-3476(86)80387-0
- 10.1097/00005792-198105000-00005 · doi:10.1097/00005792-198105000-00005
- 10.1016/0006-2952(77)90191-5 · doi:10.1016/0006-2952(77)90191-5
- 10.1056/NEJM197008132830708 · doi:10.1056/nejm197008132830708
- 10.1053/shem.2001.20861 · doi:10.1053/shem.2001.20861
- Brogard JM, Coumaros D, Franckhauser J, et al: Enzymatic uricolysis: A study of the effect of a fungal urate-oxydase. Rev Eur Etud Clin Biol 17:890,1972-895, · doi:10.1088/0031-9155/17/6/097
- 10.1016/S0022-3476(82)80259-X · doi:10.1016/s0022-3476(82)80259-x
- 10.1053/shem.2001.27079 · doi:10.1053/shem.2001.27079
- 10.3816/CLM.2008.n.003 · doi:10.3816/clm.2008.n.003
- Annemans L, Moeremans K, Lamotte M, et al: Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support Care Cancer 11:249,2003-257, · doi:10.1007/s00520-002-0435-3
- 10.1182/blood-2004-03-0888 · doi:10.1182/blood-2004-03-0888
- 10.1053/sonc.2001.20747 · DOI
- 10.1080/08998280.2005.11928082 · doi:10.1080/08998280.2005.11928082
- Friedman EA: An introduction to phosphate binders for the treatment of hyperphosphatemia in patients with chronic kidney disease. Kidney Int Suppl S2,2005-S6, · doi:10.1016/s0085-2538(15)51226-x
- 10.1007/BF00866363 · doi:10.1007/bf00866363
- 10.1007/BF00857665 · doi:10.1007/bf00857665
Cited by
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Howard, S. C., Jones, D. P., & Pui, C.-H. (2011) · New England Journal of Medicine · doi:10.1056/nejmra0904569 · Cited by 1,044
Self-citationAzoulay, E., Mokart, D., Pène, F., Lambert, J., Kouatchet, A., Mayaux, J., Vincent, F., Nyunga, M., Bruneel, F., Laisne, L.-M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.2365 · Cited by 638
Thieblemont, C., Phillips, T., Ghesquieres, H., Cheah, C. Y., Clausen, M. R., Cunningham, D., Do, Y. R., Feldman, T., Gasiorowski, R., Jurczak, W., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01725 · Cited by 584
Cairo, M. S., Coiffier, B., Reiter, A., Younes, A., & Panel, O. B. O. T. T. E. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08143.x · Cited by 570
Self-citation
Metadata
- Authors
- Coiffier, B., Altman, A., Pui, C.-H., Younes, A., & Cairo, M. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-06-01
- Volume
- 26
- Issue
- 16
- Pages
- 2767-2778
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2141234027
- Cited by
- 792
- References
- 26
- FWCI
- 37.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.